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Bovine Leukemia Virus (BLV) is distributed worldwide
and causes important economic losses on dairy farms.
Currently, there are no effective vaccines or antivirals
against BLV. Egg yolk antibodies (IgY) has many advan-
tages over mammalian IgG. Despite the higher yields, they
are non-invasively extracted from egg yolk, do not cross
react against mammalian antigens or activate the mamma-
lian complement system. In this work we evaluate the
reactivity of Igy antibodies against Bovine Leukemia Virus
p24 core protein and against the whole virus particle.
Hens were immunized by intramuscular inoculation with
purified p24 or the virus particle until the development of
high antibody-titers. Total IgY was purified from egg yolks
by ammonium sulfate precipitation. The purified egg yolk
antibodies strongly reacted with BLV particles from a per-
sistently infected cell line, with supernatants from ex vivo
cultures of PBMCs from natural infected animals and also
with purified p24 by both ELISA and Western blot. These
data suggest that chicken IgY may be a suitable platform
to produce large amounts of anti-BLV antibodies for diag-
nostic systems. Furthermore, the use of IgY for passive
immunization against BLV infection should also be
explored in order to develop new strategies to control the
disease in cattle.
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